Sanofi gets binding bids for consumer unit
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with knowledge of the matter.
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners,
Sanofi reportedly gets PE bids for consumer health unit
French pharma giant Sanofi received binding offers for its consumer health business from private equity firms PAI Partners and Clayton Dubilier & Rice, with expectations that a deal would be worth at least €15 billion,
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business.
Sanofi gets binding bids for consumer unit: Bloomberg News
Private equity firms Clayton Dubilier & Rice and PAI Partners have forwarded binding bids for Sanofi’s (NASDAQ:SNY) consumer health division as the French pharma giant looks to sell the unit in one of Europe’s biggest deals this year,
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...
FiercePharma3d
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...
Sanofi inks $1B deal to sell autoimmune disorder therapy
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...
BioSpace3d
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...
FiercePharma2d
GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...
BioPharma Dive2d
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
PMLiVE5d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...